Search results for: 'model fuels develop deceleration'

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

Microbiome research is on the rise following technological advancements and significant cost reductions in microbiome analysis. Research has unlocked the potential of microbiome in medical use cases, yielding tremendous insights on its nature, interactions, and impact within a host and in an external environment. Advanced studies on the role of mic...

Traditional training environments face patient safety risks, resource constraints, and limited exposure to rare event scenarios. Additionally, physical simulations are costly, limiting accessibility (especially in resource-constrained settings). Current simulation models lack personalization, resulting in operational complexity for hospitals due to...

Healthcare as an industry is entering a phase of rapid transformation. Institutions across the stakeholder spectrum including health insurers, providers, and therapeutic developers face the proposition of adapt or collapse. The health insurance industry particularly is evaluating all aspects of its business models, policy holder engagement, and pla...

The pharmaceutical (pharma) industry is undergoing significant regulatory changes resulting from the European Green Deal and the Paris Agreement. These changes require pharma companies to adopt more environmentally sustainable practices. With the increasing demand for drugs globally, pharma R&D and manufacturing infrastructure has grown, leading to...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides actionable insights across new developments in prebiotics, immunology, oncology, cell and gene therapies, antibody therapies, and precision medicine approaches. The TOE also encompasses technology advances across the use of AI and ML in drug discovery a...

This study explores the transformative potential of organoid technologies in advancing cancer research, precision medicine, and drug discovery. Organoids—3D cell culture systems derived from patient tumors—preserve tumor heterogeneity and provide physiologically relevant models for studying cancer biology, therapeutic response, and resistance mecha...

The SynBio field has evolved well over the past two decades, with significant technology disruptions leading to new opportunities and remarkable growth potential. Advances in SynBio technologies have transformed drug discovery and therapeutics development, accelerating the identification of novel drug targets and high-throughput compound screening ...